Keros Therapeutics Net Profit Margin Growth & History (KROS)
Keros Therapeutics's net profit margin was 35.65% for fiscal 2025.
View full Keros Therapeutics company overviewKeros Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 35.65% | +5313.20 pp |
| 2024 | 2024-12-31 | −5,277.55% | +96041.66 pp |
| 2023 | 2023-12-31 | −101,319.21% | — |
| 2021 | 2021-12-31 | −292.26% | — |
| 2019 | 2019-12-31 | −123.36% | — |
Keros Therapeutics quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | −6,459.95% | −6530.22 pp |
| Q4 2025 | 2025-12-31 | −6,093.77% | −4580.75 pp |
| Q3 2025 | 2025-09-30 | −51.04% | +13597.41 pp |
| Q2 2025 | 2025-06-30 | −168.96% | +122147.26 pp |
| Q1 2025 | 2025-03-31 | 70.27% | +52014.85 pp |
| Q4 2024 | 2024-12-31 | −1,513.02% | +26628.94 pp |
| Q3 2024 | 2024-09-30 | −13,648.45% | +479351.55 pp |
| Q2 2024 | 2024-06-30 | −122,316.22% | — |
| Q1 2024 | 2024-03-31 | −51,944.58% | — |
| Q4 2023 | 2023-12-31 | −28,141.96% | — |
| Q3 2023 | 2023-09-30 | −493,000.00% | — |
| Q2 2021 | 2021-06-30 | −15,622.00% | — |
| Q4 2019 | 2019-12-31 | −110.04% | — |
| Q3 2019 | 2019-09-30 | −141.96% | — |
| Q2 2019 | 2019-06-30 | −114.12% | — |
| Q1 2019 | 2019-03-31 | −127.32% | — |
Keros Therapeutics net profit margin trends
Between the periods ended 2019-12-31 and 2025-12-31, Keros Therapeutics's net profit margin increased from −123.36% to 35.65%, a change of +159.01 percentage points. The latest reported quarter, Q1 2026, shows −6,459.95%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Keros Therapeutics source filings ↗